AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18504551 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control
Number of subjects: 72
Study 18504551 — intervention group
Group type: COMPARATOR
Intervention: Conventional glycemic control
Number of subjects: 72
Study 16418093 — intervention group
Group type: EXPERIMENTAL
Intervention: CPR performed on the floor
Number of subjects: 62
Study 16418093 — intervention group
Group type: COMPARATOR
Intervention: CPR performed on a moving stretcher
Number of subjects: 62
Study 14520143 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid 10 mg/kg iv every 8 h (with option to switch to oral linezolid 10 mg/kg every 8 h)
Number of subjects: 120
Study 14520143 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin 10 to 15 mg/kg every 6 to 24 h
Number of subjects: 120
Study 14520143 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 120
Study 14520143 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 120
Study 14520143 — intervention group
Group type: EXPERIMENTAL
Intervention: Linezolid and Vancomycin
Number of subjects: 120
Study 11090730 — intervention group
Group type: COMPARATOR
Intervention: succinylcholine 1.5 mg/kg
Number of subjects: 30
Study 11090730 — intervention group
Group type: EXPERIMENTAL
Intervention: rocuronium bromide 0.6 mg/kg
Number of subjects: 30
Study 11090730 — intervention group
Group type: COMPARATOR
Intervention: atracurium
Number of subjects: 30
Study 8982415 — intervention group
Group type: EXPERIMENTAL
Intervention: Tap water iontophoresis in addition to two-sided steroid-free topical therapy
Number of subjects: 20
Study 8982415 — intervention group
Group type: COMPARATOR
Intervention: Control side (not treated with tap water iontophoresis)
Number of subjects: 20
Study 1547175 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical adhesiolysis
Number of subjects: 48
Study 1547175 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surgery)
Number of subjects: 48
Study 3903678 — intervention group
Group type: EXPERIMENTAL
Intervention: UVB (group B)
Number of subjects: 106
Study 3903678 — intervention group
Group type: EXPERIMENTAL
Intervention: UVAB (group AB)
Number of subjects: 106
Study 31091508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.6 mg/kg)
Number of subjects: 126
Study 31091508 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac (30 mg)
Number of subjects: 126
Study 31091508 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine
Number of subjects: 126
Study 28779006 — intervention group
Group type: EXPERIMENTAL
Intervention: TREX dosing
Number of subjects: 60
Study 28779006 — intervention group
Group type: COMPARATOR
Intervention: Monthly dosing transitioned to PRN
Number of subjects: 60
Study 28779006 — intervention group
Group type: EXPERIMENTAL
Intervention: TREX subjects transitioned to PRN
Number of subjects: 60
Study 27599170 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage with lotion
Number of subjects: 76
Study 27599170 — intervention group
Group type: COMPARATOR
Intervention: Massage without lotion
Number of subjects: 76
Study 27599170 — intervention group
Group type: COMPARATOR
Intervention: Non-massage control
Number of subjects: 76
Study 24667391 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose remifentanil (1.2 μg kg(‐1) min(‐1))
Number of subjects: 60
Study 24667391 — intervention group
Group type: COMPARATOR
Intervention: Regular dose remifentanil (0.2 μg kg(‐1) min(‐1))
Number of subjects: 60
Study 22464116 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates-based therapy
Number of subjects: 31
Study 22464116 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapeutic intervention)
Number of subjects: 31
Study 20421611 — intervention group
Group type: EXPERIMENTAL
Intervention: English vocabulary instruction enhanced with Spanish bridging
Number of subjects: 22
Study 20421611 — intervention group
Group type: COMPARATOR
Intervention: English-only vocabulary instruction
Number of subjects: 22
Study 18362931 — intervention group
Group type: EXPERIMENTAL
Intervention: Aex plus GM-CSF
Number of subjects: 40
Study 18362931 — intervention group
Group type: COMPARATOR
Intervention: Aex alone
Number of subjects: 40
Study 16036128 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxide and resin‐modified glass ionomer
Number of subjects: 60
Study 16036128 — intervention group
Group type: COMPARATOR
Intervention: Dentin hybridization only
Number of subjects: 60
Study 12611359 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-ASD brain-controlled switch with imagined voluntary movements (able-bodied subjects)
Number of subjects: 4
Study 12611359 — intervention group
Group type: EXPERIMENTAL
Intervention: LF-ASD brain-controlled switch with imagined voluntary movements (spinal-cord injury subjects)
Number of subjects: 4
Study 10337843 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiving Effectiveness Model variables
Number of subjects: 62
Study 7492155 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey hydrolysate (n = 27)
Number of subjects: 85
Study 7492155 — intervention group
Group type: EXPERIMENTAL
Intervention: Casein hydrolysate (n = 32)
Number of subjects: 85
Study 7492155 — intervention group
Group type: COMPARATOR
Intervention: Usual diet (Control group, n = 26)
Number of subjects: 85
Study 1855355 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine
Number of subjects: 74
Study 1855355 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 74
Study 7073809 — intervention group
Group type: EXPERIMENTAL
Intervention: Diflorasone diacetate ointment 0.05%
Number of subjects: 100
Study 7073809 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate ointment 0.05%
Number of subjects: 100
Study 31525673 — intervention group
Group type: EXPERIMENTAL
Intervention: REHACOM computerized cognitive remediation intervention (n = 36)
Number of subjects: 86
Study 31525673 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (n = 50) consisting of 24 one-hour sessions addressed twice a week
Number of subjects: 86
Study 31525673 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (REHACOM and control)
Number of subjects: 86
Study 29056103 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted dietary advice solutions developed per metabotype using a decision tree approach.
Number of subjects: 1607
Study 29056103 — intervention group
Group type: COMPARATOR
Intervention: Personalised dietary advice delivered by nutritionists to Food4Me study participants.
Number of subjects: 1607
Study 26573024 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene-HMG
Number of subjects: 180
Study 26573024 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole-HMG
Number of subjects: 180
Study 26573024 — intervention group
Group type: COMPARATOR
Intervention: Non-LUF group
Number of subjects: 180
Study 26573024 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle size 18-19.9 mm
Number of subjects: 180
Study 26573024 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicle size 20-21.9 mm
Number of subjects: 180
Study 25018097 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-16/18 vaccine
Number of subjects: 7466
Study 25018097 — intervention group
Group type: COMPARATOR
Intervention: Control (Hepatitis A vaccine)
Number of subjects: 7466
Study 21102369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine pledget
Number of subjects: 24
Study 21102369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical proparacaine
Number of subjects: 24
Study 21102369 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival lidocaine injection
Number of subjects: 24
Study 21102369 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tetracaine
Number of subjects: 24
Study 19302646 — intervention group
Group type: EXPERIMENTAL
Intervention: Frova single-use tracheal tube introducer
Number of subjects: 72
Study 19302646 — intervention group
Group type: EXPERIMENTAL
Intervention: Eschmann multiple-use introducer
Number of subjects: 72
Study 19302646 — intervention group
Group type: COMPARATOR
Intervention: Pro-Breathe single-use tracheal tube introducer
Number of subjects: 72
Study 19302646 — intervention group
Group type: COMPARATOR
Intervention: new Portex single-use tracheal tube introducer
Number of subjects: 72
Study 19302646 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-Breathe, new Portex, and Frova single-use introducers
Number of subjects: 72
Study 17319771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC adhesive
Number of subjects: 40
Study 17319771 — intervention group
Group type: COMPARATOR
Intervention: Transbond Plus system
Number of subjects: 40
Study 14998806 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 11448899 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 25 mg HRS‐3/A9 for 4 days
Number of subjects: 16
Study 11448899 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hour infusion of 25 mg HRS‐3/A9 every other day
Number of subjects: 16
Study 11448899 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin 2 pretreatment before the second BiMAb course
Number of subjects: 16
Study 11448899 — intervention group
Group type: EXPERIMENTAL
Intervention: HRS‐3/A9 treatment
Number of subjects: 16
Study 9602194 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (≤ 20 ppm for 1 to 4 days)
Number of subjects: 24
Study 9602194 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrotyrosine detection
Number of subjects: 24
Study 7985146 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcardiac galvanization (TG)
Number of subjects: 110
Study 2662065 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release naproxen (Naprosyn CR), 750 mg daily
Number of subjects: 520
Study 2662065 — intervention group
Group type: COMPARATOR
Intervention: Standard Naprosyn, 750 mg daily
Number of subjects: 520
Study 2662065 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled release naproxen (Naprosyn CR)
Number of subjects: 520
Study 2662065 — intervention group
Group type: COMPARATOR
Intervention: Standard Naprosyn
Number of subjects: 520
Study 29558822 — intervention group
Group type: EXPERIMENTAL
Intervention: AHCC®
Number of subjects: 0
Study 29558822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28972245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 246
Study 28972245 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical training
Number of subjects: 246
Study 28972245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplementation
Number of subjects: 246
Study 28972245 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination intervention
Number of subjects: 246
Study 28972245 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 246
Study 25700754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryton Side Branch Stent
Number of subjects: 326
Study 25700754 — intervention group
Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 326
Study 23649997 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with temozolomide (TMZ) - 200 mg/m² for 5 days post-surgery, followed by 75 mg/m² daily during radiotherapy, and 150-200 mg/m² for 5 days every 28 days after radiotherapy.
Number of subjects: 58
Study 23649997 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone - involved-field radiotherapy in 2 Gy fractions daily for 6 weeks (total of 60 Gy).
Number of subjects: 58
Study 20587052 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose 1, 6 diphosphate (FDP)
Number of subjects: 0
Study 20587052 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 0
Study 18398094 — intervention group
Group type: EXPERIMENTAL
Intervention: Six TAC cycles (n = 686)
Number of subjects: 1390
Study 18398094 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight TAC cycles (n = 704)
Number of subjects: 1390
Study 16809799 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum chloride (LaCl3) intravenous infusion (120 microg elemental lanthanum over a 4-hour period)
Number of subjects: 24
Study 16809799 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewable lanthanum carbonate (La2(CO3)3) tablets (1-g oral dose; 4 x 250 mg elemental lanthanum)
Number of subjects: 24
Study 16809799 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 24
Study 14535906 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA insertion by the lateral approach with cuff partially inflated (group LP)
Number of subjects: 62
Study 14535906 — intervention group
Group type: COMPARATOR
Intervention: LMA insertion by the midline approach with cuff completely deflated (group MD)
Number of subjects: 62
Study 11057850 — intervention group
Group type: EXPERIMENTAL
Intervention: Acenocoumarol (INR 2.0‐3.0)
Number of subjects: 100
Study 11057850 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (4000 anti‐Xa units once a day)
Number of subjects: 100
Study 9284854 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (0.20 mg/kg every 12 hours) + Furosemide (1 mg/kg)
Number of subjects: 36
Study 9284854 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin (0.20 mg/kg every 12 hours)
Number of subjects: 36
Study 8300705 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanner skin mesher with expansion ratios of 1.5:1 and 3:1
Number of subjects: 20
Study 8300705 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioplasty skin mesher with expansion ratios of 2:1 and 4:1
Number of subjects: 20
Study 3455968 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg of AA per day for two weeks
Number of subjects: 11
Study 3455968 — intervention group
Group type: COMPARATOR
Intervention: 0 mg (placebo) per day for four weeks
Number of subjects: 11
Study 3455968 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg per day for three weeks
Number of subjects: 11
Study 3455968 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 mg per day for four weeks
Number of subjects: 11
Study 29072472 — intervention group
Group type: EXPERIMENTAL
Intervention: Growing Pro-Social (GPS) Program
Number of subjects: 254
Study 29072472 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 254
Study 27022882 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning (IPOC) immediately after thrombus aspiration (TA) followed by stenting of the IRA
Number of subjects: 72
Study 27022882 — intervention group
Group type: COMPARATOR
Intervention: Conventional percutaneous coronary intervention (PCI), including TA followed by stenting of the IRA
Number of subjects: 72
Study 24018106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-propofol
Number of subjects: 46
Study 24018106 — intervention group
Group type: COMPARATOR
Intervention: Ketamine-propofol
Number of subjects: 46
Study 22353456 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 50
Study 22353456 — intervention group
Group type: COMPARATOR
Intervention: 3% mepivacaine
Number of subjects: 50
Study 22353456 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine and 3% mepivacaine
Number of subjects: 50
Study 20728687 — intervention group
Group type: EXPERIMENTAL
Intervention: GBG‐response cost
Number of subjects: 6
Study 20728687 — intervention group
Group type: EXPERIMENTAL
Intervention: GBG‐reinforcement
Number of subjects: 6
Study 19064449 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent education programs
Number of subjects: 58
Study 15752096 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc tablets
Number of subjects: 84
Study 15752096 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine tablets and mouthwash
Number of subjects: 84
Study 15752096 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyophilized lactic acid-forming bacteria
Number of subjects: 84
Study 15752096 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 84
Study 12677364 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine-based immunosuppressive therapy
Number of subjects: 72
Study 11971305 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing professional education programmes
Number of subjects: 0
Study 11971305 — intervention group
Group type: COMPARATOR
Intervention: Randomised control trial (RCT) methodology
Number of subjects: 0
Study 8799424 — intervention group
Group type: EXPERIMENTAL
Intervention: RO‐11 at a daily s.c. dose of 2,500 anti‐FXa IU
Number of subjects: 100
Study 8799424 — intervention group
Group type: COMPARATOR
Intervention: Calcium unfractionated heparin (UH) at a s.c. dose of 5,000 IU 12 hourly
Number of subjects: 100
Study 1453197 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous therapy
Number of subjects: 0
Study 1453197 — intervention group
Group type: COMPARATOR
Intervention: Intermittent therapy
Number of subjects: 0
Study 1453197 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline and change in scores for physical well-being (PWB), mood, pain, and QLI after the first three treatment cycles
Number of subjects: 0
Study 1453197 — intervention group
Group type: EXPERIMENTAL
Intervention: QLI and PWB scores
Number of subjects: 0
Study 1453197 — intervention group
Group type: EXPERIMENTAL
Intervention: QL improvement
Number of subjects: 0
Study 6606942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of glucagon
Number of subjects: 133
Study 6606942 — intervention group
Group type: COMPARATOR
Intervention: 1 ml of saline placebo
Number of subjects: 133
Study 31006282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly titrated oral misoprostol
Number of subjects: 150
Study 31006282 — intervention group
Group type: COMPARATOR
Intervention: 2-hourly static oral misoprostol
Number of subjects: 150
Study 29652078 — intervention group
Group type: EXPERIMENTAL
Intervention: Alogliptin
Number of subjects: 5380
Study 29652078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5380
Study 25847293 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Mailings (RM): eight Forever Free RP booklets sent to participants over 12 months
Number of subjects: 3458
Study 25847293 — intervention group
Group type: COMPARATOR
Intervention: Usual Care: standard intervention provided by the quitline, including brief counseling and nicotine replacement therapy
Number of subjects: 3458
Study 25847293 — intervention group
Group type: EXPERIMENTAL
Intervention: Massed Mailings: all eight Forever Free RP booklets sent upon enrollment
Number of subjects: 3458
Study 25458046 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 150
Study 25458046 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 150
Study 25458046 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 150
Study 22378736 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA intake below the median
Number of subjects: 408
Study 22378736 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 PUFA intake above the median
Number of subjects: 408
Study 20349229 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium 1,000 mg for 1 week followed by Vitamin D3 1,000 i.u. daily for 7 weeks
Number of subjects: 22
Study 20349229 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 1,000 i.u. daily for 7 weeks followed by Calcium 1,000 mg for 1 week
Number of subjects: 22
Study 20349229 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamin D together
Number of subjects: 22
Study 18387078 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 497
Study 18387078 — intervention group
Group type: COMPARATOR
Intervention: Neutral Protamine Hagedorn (NPH) insulin
Number of subjects: 497
Study 15777441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose vaginal misoprostol 25 microg every 4 hours (maximum of six doses)
Number of subjects: 268
Study 15777441 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal gel 1‐2 mg 6 hourly (maximum of 3 mg in 24 hours)
Number of subjects: 268
Study 15777441 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose vaginal misoprostol
Number of subjects: 268
Study 15777441 — intervention group
Group type: COMPARATOR
Intervention: Dinoprostone vaginal gel
Number of subjects: 268
Study 12139289 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent episodes of AF
Number of subjects: 0
Study 12139289 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrequent episodes of AF
Number of subjects: 0
Study 10459118 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene
Number of subjects: 11
Study 10459118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 7869560 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual snow shoveling
Number of subjects: 10
Study 7869560 — intervention group
Group type: COMPARATOR
Intervention: Automated snow removal
Number of subjects: 10
Study 2691106 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound five-Shen herbal drink (CFSHD) - Group I
Number of subjects: 600
Study 2691106 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound five-Shen herbal drink (CFSHD) - Group II
Number of subjects: 600
Study 2691106 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 600
Study 608366 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (Ritalin)
Number of subjects: 0
Study 608366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31284323 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR TKA
Number of subjects: 120
Study 31284323 — intervention group
Group type: COMPARATOR
Intervention: PS TKA
Number of subjects: 120
Study 30844425 — intervention group
Group type: EXPERIMENTAL
Intervention: LPP (Lolium perenne peptide)
Number of subjects: 32
Study 30844425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 28440812 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (30mg per day)
Number of subjects: 34
Study 23903088 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (100 U) injected into the pectoralis muscle
Number of subjects: 23
Study 23903088 — intervention group
Group type: COMPARATOR
Intervention: Placebo injected into the contralateral side
Number of subjects: 23
Study 23670576 — intervention group
Group type: EXPERIMENTAL
Intervention: Endostar (7.5 mg/m²) plus dacarbazine (250 mg/m²)
Number of subjects: 110
Study 23670576 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus dacarbazine (250 mg/m²)
Number of subjects: 110